Advancing Zervimesine (CT1812) towards late-stage trials for dementia with Lewy bodies (DLB) psychosis Fully funded $80 million Phase 2 START trial readout expected in the second half of 2027 PURCHASE ...

Cognition Therapeutics (NASDAQ:CGTX) used its fourth-quarter and full-year 2025 earnings call to outline a shift in ...

Fear of dementia is rising almost as fast as the condition itself. And where fear grows, so does a market promising protection. Among the most popular offerings is Ginkgo biloba, a centuries-old ...

EXCLUSIVE: Cognition has signed Scottish actor Grant O’Rourke following the award-winning Sundance debut of The Incomer, a ...

Cognition Therapeutics, Inc. is a clinical-stage biopharmaceutical company dedicated to helping millions of families seeking effective treatments for devastating neurodegenerative diseases through the ...

Amid an influx of new drugs targeting one of the believed root causes of Alzheimer’s disease, a new symptomatic med has hit the scene, courtesy of Vancouver’s Alpha Cognition. On Monday, the FDA gave ...

Backed by $200 million in funding, 28-year-old Scott Wu and his team of competitive coders at Cognition are building an AI tool that can program entirely on its own, like an “army of junior engineers.